Edge Therapeutics (EDGE) Given News Impact Score of 0.09

News coverage about Edge Therapeutics (NASDAQ:EDGE) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Edge Therapeutics earned a news impact score of 0.09 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 44.1695022220575 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media stories that may have impacted Accern’s rankings:

EDGE has been the subject of several recent analyst reports. Zacks Investment Research upgraded Edge Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. BidaskClub lowered Edge Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 14th.

Shares of Edge Therapeutics (EDGE) traded down 2.69% on Tuesday, hitting $9.41. The company’s stock had a trading volume of 71,914 shares. The stock has a 50-day moving average price of $10.58 and a 200 day moving average price of $9.88. The firm’s market cap is $290.31 million. Edge Therapeutics has a one year low of $7.30 and a one year high of $13.50.

Edge Therapeutics (NASDAQ:EDGE) last released its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.44) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.44). Equities research analysts predict that Edge Therapeutics will post ($1.87) EPS for the current year.

In other news, CEO Brian A. Leuthner sold 2,500 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $10.37, for a total value of $25,925.00. Following the completion of the sale, the chief executive officer now owns 117,736 shares of the company’s stock, valued at approximately $1,220,922.32. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Brian A. Leuthner sold 7,500 shares of the stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $10.53, for a total transaction of $78,975.00. Following the completion of the sale, the insider now directly owns 125,236 shares of the company’s stock, valued at approximately $1,318,735.08. The disclosure for this sale can be found here. In the last three months, insiders sold 31,000 shares of company stock valued at $319,190. Corporate insiders own 36.19% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Edge Therapeutics (EDGE) Given News Impact Score of 0.09” was originally posted by Stock Observer and is owned by of Stock Observer. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.thestockobserver.com/2017/09/12/edge-therapeutics-edge-given-news-impact-score-of-0-09.html.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply